Therapy for relapsed/refractory disease should be resolved based on prior therapy and likewise The main reason why the first treatment method was now not proper (e.g., refractoriness vs. intolerance). Ibrutinib is the current gold common therapy for people with relapsed/refractory illness, determined by the results of a number of period I-III trial